Literatur
-
1
Lok C.
Blood product from cattle wins approval for use in humans.
Nature.
2001;
410
855
-
2 Riess J G. Fluorocarbon-based-Oxygen-Delivery:Basic Principles and Product Development. In: Chang TM (Hrsg). Blood substitutes: principles, methods, products and clinical trials. Basel: Karger Landes Systems 1998
-
3
Spence R K.
Perfluorocarbons in the twenty-first century: clinical applications as transfusion alternatives.
Artif Cells Blood Substit Immobil Biotechnol.
1995;
23
367-380
-
4 Keipert P E. Perfluorochemical emulsions: future alternatives to transfusion. In: Chang TM (Hrsg). Blood substitutes: principles, methods, products and clinical trials. Basel: Karger Landes Systems 1998
-
5 Ohyanagi H. Perfluorochemical Emulsions as Blood Substitutes: Clinical Data and new Applications. In: Tsuchida E (Hrsg). Artificial red cells. Chicester: John Wiley and Sons 1995
-
6
Jager L J, Lutz J.
Phagocytosis of colloidal carbon after administration of perfluorochemicals of first and second generation.
Adv Exp Med Biol.
1994;
345
221-226
-
7
Bottalico L A, Betenksy H T, Min Y B, Weinstock S B.
Perfluorochemical emulsions decrease kupffer cell phagocytosis.
Hepatology.
1991;
14
169-174
-
8
Chang T M.
Red blood cell substitutes.
Baillieres Best Pract Res Clin Haematol.
2000;
13
651-667
-
9
Dinkelmann S, Rohlke W, Meinert H, Northoff H.
A system establishment compatibility profiles for artificial oxygen carriers and other substances.
Artif Cells Blood Substit Immobil Biotechnol.
2001;
29
57-70
-
10
Forman M B, Pitarys C J, Vildibill H D, Lambert T L, Ingram D A, Virmani R, Murray J J.
Pharmacologic pertubation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion.
J Am Coll Cardiol.
1992;
19
205-216
-
11
Mitsuno T, Ohyanagi H, Naito R.
Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases.
Ann Surg.
1982;
195
60-69
-
12
Spence R K, Norcross E D, Costabile J, McCoy S, Cernaianu A C, Alexander J B, Pello M J, Atabek U, Camishion R C.
Perfluorocarbons as blood substitutes: The early years. Experience with Fluosol DA-20% in the 1980s.
Artif Cells Blood Substit Immobil Biotechnol.
1994;
22
955-963
-
13
Wall T C, Califf R M, Blankenship J, Talley J D, Tannenbaum M, Schwaiger M, Gacioch G, Cohen M D, Sanz M, Leimberger J D,.
Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group.
Circulation.
1994;
90
114-120
-
14
Ohyanagi H, Saitoh Y.
Development and clinical application of perfluorochemical artificial blood.
Int J Artif Organs.
1986;
9
363-368
-
15
Hong F, Shastri K A, Logue G L, Spaulding M B.
Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies.
Transfusion.
1991;
31
642-647
-
16 Kaufman R J. Clinical Development of Perfluorocarbon-based Emulsions as Red Cell Substitutes. In: Winslow RM, Vandegriff KD, Intaglietta M (Hrsg). Blood Substitutes: Physiological Basis of Efficacy. Boston: Birkhäuser 1995
-
17
Spahn D R, van Brempt R, Theilmeier G, Reibold J P, Welte M, Heinzerling H, Birck K M, Keipert P E, Messmer K.
Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group.
Anesthesiology.
1999;
91
1195-1208
-
18
Greenspan J S, Wolfson M R, Shaffer T H.
Liquid ventilation: clinical experiences.
Biomed Instrum Technol.
1999;
33
253-259
-
19
Hirschl R B, Conrad S, Kaiser R, Zwischenberger J B, Bartlett R H, Booth F, Cardenas V.
Partial liquid ventilation in adult patients with ARDS: a multicenter phase I-II trial. Adult PLV Study Group.
Ann Surg.
1998;
228
692-700
-
20
Pelura T J.
Clinical experience with AF0150 (Imagent US), a new ultrasound contrast agent.
Acad Radiol.
1998;
5
(Suppl 1)
S69-S71
-
21
Looker D, Abbott-Brown D, Cozart P, Durfee S, Hoffman S, Mathews A J, Miller-Roehrich J, Shoemaker S, Trimble S, Fermi G ,.
A human recombinant haemoglobin designed for use as a blood substitute.
Nature.
1992;
356
258-260
-
22
Rao M J, Schneider K, Chait B T, Chao T L, Keller H, Anderson S, Manjula B N, Kumar R, Acharya A S.
Recombinant hemoglobin A produced in transgenic swine: structural equivalence with human hemoglobin A.
Artif Cells Blood Substit Immobil Biotechnol.
1994;
22
695-700
-
23 Barnikol W K, Burkhard O, Poetzschke H, Domack U, Dinkelmann S, Guth S, Fiedler B, Manz B. New artificial oxygen carriers made of pegulated pyridoxylated porcine haemoglobin (P4Hb). Comparative Biochemistry and Physiology; im Druck 2002
-
24 Winslow R M. Hemoglobin-based red cell substitutes. London: Johns Hopkins University Press 1992
-
25
Saxena R, Wijnhoud A D, Man i n, van den Meiracker A H, Boomsma F, Przybelski R J, Koudstaal P J.
Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man.
J Hypertens.
1998;
16
1459-1465
-
26
Sloan E P, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory M N, Rodman G.
Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial.
JAMA.
1999;
282
1857-1864
-
27
Saxena R, Wijnhoud A D, Carton H, Hacke W, Kaste M, Przybelski R J, Stern K N, Koudstaal P J.
Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke.
Stroke.
1999;
30
993-996
-
28
Hill S E.
Oxygen therapeutics-current concepts.
Can J Anaesth.
2001;
48
S32-S40
-
29
Cheng D C.
Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery.
Can J Anaesth.
2001;
48
S41-S48
-
30 Adamson J G, Moore C. Hemolink, an o-Raffinose crosslinked hemoglobin-based oxygen carrier. In: Chang TM (Hrsg). Blood substitutes: principles, methods, products and clinical trials. Basel: Karger Landes Systems 1998
-
31 Gould S A, Sehgal L R, Sehgal H L, DeWoskin R, Moss G S. The clinical development of human polymerized hemoglobin. In: Chang TM (Hrsg). Blood substitutes: principles, methods, products and clinical trials. Basel: Karger Landes Systems 1998
-
32
Gould S A, Moore E E, Hoyt D B, Burch J M, Haenel J B, Garcia J, DeWoskin R, Moss G S.
The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery.
J Am Coll Surg.
1998;
187
113-120
-
33
Privalle C, Talarico T, Keng T, DeAngelo J.
Pyridoxalated hemoglobin polyoxyethylene: a nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock.
Free Radic Biol Med.
2000;
28
1507-1517
-
34
Hertzman C M, Keipert P E, Chang T M.
Serum antibody titers in rats receiving repeated small subcutaneous injections of hemoglobin or polyhemoglobin: a preliminary report.
Int J Artif Organs.
1986;
9
179-182
-
35
Chang T M, Lister C, Nishiya , Varma R.
Immunological effects of hemoglobin, encapsulated hemoglobin, polyhemoglobin and conjugated hemoglobin using different immunization schedules.
Biomater Artif Cells Immobilization Biotechnol.
1992;
20
611-618
-
36
Bleeker W K, Zappeij L M, den Boer P J, Agterberg J A, Rigter G M, Bakker J C.
Evaluation of the immunogenicity of polymerized hemoglobin solutions in a rabbit model.
Artif Cells Blood Substit Immobil Biotechnol.
1995;
23
461-468
-
37
Hamilton R G, Kelly N, Gawryl M S, Rentko V T.
Absence of immunopathology associated with repeated IV administration of bovine Hb- based oxygen carrier in dogs.
Transfusion.
2001;
41
219-225
-
38
Patel M J, Webb E J, Shelbourn T E, Mattia-Goldberg C, George A J, Zhang F, Moore E G, Nelson D J.
Absence of immunogenicity of diaspirin cross-linked hemoglobin in humans.
Blood.
1998;
91
710-716
-
39
Lee R, Neya K, Svizzero T A, Vlahakes G J.
Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions.
J Appl Physiol.
1995;
79
236-242
-
40
Faivre B, Menu P, Labrude P, Grandgeorge M, Vigneron C.
Methemoglobin formation after administration of hemoglobin conjugated to carboxylate dextran in guinea pigs. Attempts to prevent the oxidation of hemoglobin.
Artif Cells Blood Substit Immobil Biotechnol.
1994;
22
551-558
-
41
Bush S, Marshall T, Spicuzza J, Nelson D.
Diaspirin crosslinked hemoglobin (DCLHb): bioanalytical studies in swine.
Artif Cells Blood Substit Immobil Biotechnol.
1994;
22
917-922
-
42
Yang T, Olsen K W.
Enzymatic protection from autoxidation for crosslinked hemoglobins.
Artif Cells Blood Substit Immobil Biotechnol.
1994;
22
709-717
-
43
Simoni J, Simoni G, Lox C D, Feola M.
Reaction of human endothelial cells to bovine hemoglobin solutions and tumor necrosis factor.
Artif Cells Blood Substit Immobil Biotechnol.
1994;
22
777-787
-
44 Alayash A I, Brockner Ryan B A, McLeod L L, Goldman D W, Cashon R E. Cell-free hemoglobin and tissue oxidants: probing the mechanisms of hemoglobin cytotoxicity. In: Chang TM (Hrsg). Blood Substitutes: principles, emthods, products and clinical trials. Basel: Karger Landes Systems 1998
-
45
Su D, Roth R I, Yoshida M, Levin J.
Hemoglobin increases mortality from bacterial endotoxin.
Infect Immun.
1997;
65
1258-1266
-
46
White C T, Murray A J, Smith D J, Greene J R, Bolin R B.
Synergistic toxicity of endotoxin and hemoglobin.
J Lab Clin Med.
1986;
108
132-137
-
47
Zuckerman S H, Evans G F, Bryan N.
Interactions of recombinant hemoglobin (rHb1.1) and endotoxin in vivo: effects on systemic tumor necrosis factor and interleukin-6 levels in lethal and sublethal murine models of endotoxemia.
J Lab Clin Med.
1997;
130
427-435
-
48
Whiteford M, Spirig A, Rudolph A, Neville L, Abdullah F, Feuerstein G, Rabinovici R.
Effect of liposome-encapsulated hemoglobin on the development of endotoxin-induced shock in the rat.
Shock.
1998;
9
428-433
-
49
Bone H G, Schenarts P J, Booke M, McGuire R, Harper D, Traber L D, Traber D L.
Oxalated pyridoxalated hemoglobin polyoxyethylene conjugate normalizes the hyperdynamic circulation in septic sheep.
Crit Care Med.
1997;
25
1010-1018
-
50
Heneka M T, Loschmann P A, Osswald H.
Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat.
J Clin Invest.
1997;
99
47-54
-
51
Winslow R M.
alphaalpha-crosslinked hemoglobin: was failure predicted by preclinical testing?.
Vox Sang.
2000;
79
1-20
-
52
Kasper S M, Grune F, Walter M, Amr N, Erasmi H, Buzello W.
The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery.
Anesth Analg.
1998;
87
284-291
-
53
Doherty D H, Doyle M P, Curry S R, Vali R J, Fattor T J, Olson J S, Lemon D D.
Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin.
Nat Biotechnol.
1998;
16
672-676
-
54
Rioux F, Harvey N, Moisan S, Lariviere R, Lebel M, Grose J H, Burhop K.
Nonpeptide endothelin receptor antagonists attenuate the pressor effect of diaspirin-crosslinked hemoglobin in rat.
Can J Physiol Pharmacol.
1999;
77
188-194
-
55
Ledvina M A, Hart J, Bina S, Jing M, Muldoon S.
Endothelin plays a role in contractions of isolated pig pulmonary vessels induced by diaspirin cross-linked hemoglobin.
J Lab Clin Med.
1999;
133
478-487
-
56
Gould S A, Moss G S.
Clinical development of human polymerized hemoglobin as a blood substitute.
World J Surg.
1996;
20
1200-1207
-
57
Baldwin A L.
Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery.
Am J Physiol.
1999;
277
H650-H659
-
58
Rohlfs R J, Bruner E, Chiu A, Gonzales A, Gonzales M L, Magde D, Magde M D, Vandegriff K D, Winslow R M.
Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide.
J Biol Chem.
1998;
273
12128-12134
-
59 Vandegriff K D, Winslow R M. A theoretical analysis of oxygen transport: a new strategy for the design of hemoglobin-based red cell substitutes. In: Winslow RM, Vandegriff KD, Intaglietta M (Hrsg). Blood Substitutes: Physiological Basis of Efficacy. Boston: Birkhäuser 1995
-
60 Tsai A G, Kerger H, Intaglietta M. Microcirculatory consequences of blood substitution with αα-Hemoglobin. In: Winslow RM, Vandegriff KD, Intaglietta M (Hrsg). Blood Substitutes: Physiological Basis of Efficacy. Boston: Birkhäuser 1995
-
61
Page T C, Light W R, McKay C B, Hellums J D.
Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance.
Microvasc Res.
1998;
55
54-64
-
62
McCarthy M R, Vandegriff K D, Winslow R M.
The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers.
Biophys Chem.
2001;
92
103-117
-
63
Tsai C H, Fang T Y, Ho N T, Ho C.
Novel recombinant hemoglobin, rHb (beta N108Q), with low oxygen affinity, high cooperativity, and stability against autoxidation.
Biochemistry.
2000;
39
13719-13729
-
64
Nakai K, Togashi H, Yasukohchi T, Sakuma I, Fujii S, Yoshioka M, Satoh H, Kitabatake A.
Preparation and characterization of SNO-PEG-hemoglobin as a candidate for oxygen transporting material.
Int J Artif Organs.
2001;
24
322-328
-
65
Vandegriff K D.
Haemoglobin-based oxygen carriers.
Expert Opin Investig Drugs.
2000;
9
1967-1984
-
66
Nakai K, Ohta T, Sakuma I, Akama K, Kobayashi Y, Tokuyama S, Kitabatake A, Nakazato Y, Takahashi T A, Sadayoshi S.
Inhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: comparison between acellular hemoglobin derivatives and cellular hemoglobins.
J Cardiovasc Pharmacol.
1996;
28
115-123
-
67
Phillips W T, Klipper R W, Awasthi V D, Rudolph A S, Cliff R, Kwasiborski V, Goins B A.
Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute.
J Pharmacol Exp Ther.
1999;
288
665-670
-
68
Yu W P, Chang T M.
Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: preparation and characterization.
Artif Cells Blood Substit Immobil Biotechnol.
1996;
24
169-183
1 Diese Arbeit wird in Infusionstherapie und Transfusionsmedizin in englischer Sprache veröffentlicht
Korrespondenzadresse:
Prof. Dr. Hinnak Northoff
Institut für Transfusionsmedizin, Eberhard-Karls-Universität Tübingen
Otfried-Mueller-Straße 4/1
72076 Tübingen
eMail: hinnak.northoff@med.uni-tuebingen.de
